Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 11.71 USD 3.63% Market Closed
Market Cap: 447.6m USD

Net Margin

-168.2%
Current
Declining
by 107.6%
vs 3-y average of -60.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-168.2%
=
Net Income
$-103.5m
/
Revenue
$61.5m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-168.2%
=
Net Income
$-103.5m
/
Revenue
$61.5m

Peer Comparison

Country Company Market Cap Net
Margin
US
Entrada Therapeutics Inc
NASDAQ:TRDA
447.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 87% of companies in the United States of America
Percentile
13th
Based on 15 072 companies
13th percentile
-168.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Entrada Therapeutics Inc
Glance View

Market Cap
447.6m USD
Industry
Biotechnology

Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

TRDA Intrinsic Value
5.04 USD
Overvaluation 57%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-168.2%
=
Net Income
$-103.5m
/
Revenue
$61.5m
What is Entrada Therapeutics Inc's current Net Margin?

The current Net Margin for Entrada Therapeutics Inc is -168.2%, which is below its 3-year median of -60.6%.

How has Net Margin changed over time?

Over the last 3 years, Entrada Therapeutics Inc’s Net Margin has increased from -315.2% to -168.2%. During this period, it reached a low of -315.2% on Mar 31, 2023 and a high of 43.6% on Jun 30, 2024.

Back to Top